John Paul Seenan

Dr. John Paul Seenan

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2020 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
MLMichael Logan
Michael Logan
KGKonstantinos Gerasimidis
Konstantinos Gerasimidis
Vaios SvolosVaios Svolos
Vaios Svolos
BNBen Nichols
Ben Nichols
SMSimon Milling
Simon Milling
KGKonstantinos Gerasimidis
Konstantinos Gerasimidis
Summary: Background: Exclusive enteral nutrition (EEN) is an effective treatment for Crohn's disease.Aims: To investigate the hypothesis that ingredients of EEN formulas are unlikely to initiate a disease flare and that their dietary elimination is not essential for disease amelioration.Methods: We performed compositional analysis of EEN formulas with evidence of efficacy in management of active Crohn's disease. Macronutrient content was compared against the dietary reference values (DRV), the UK National Diet and Nutrition Survey (NDNS) and intake of Crohn's disease children. Food additives were cross‐referenced against the FAO/WHO database.Results: Sixty‐one formulas were identified with variable composition (carbohydrates [22.8%‐89.3%], protein [7.8%‐30.1%], fat [0%‐52.5%]). Maltodextrin, milk protein and vegetable/plant oils were the commonest macronutrient sources. Their n‐6:n‐3 fatty acid ratio varied from 0.25 to 46.5. 56 food additives were identified (median per formula: 11). All formulas were lactose‐free, gluten‐free, and 82% lacked fibre. The commonest food additives were emulsifiers, stabilisers, antioxidants, acidity regulators and thickeners. Food additives, implicated in Crohn's disease aetiology, were present in formulas (modified starches [100%], carrageenan [22%], carboxymethyl cellulose [13%] and polysorbate 80 [5%]). Remission rates did not differ between EEN formulas with and without those food additives. Analysis including only formulas from randomised controlled trials (RCTs) retained in the latest Cochrane meta‐analysis produced similar findings. EEN formulas contained less energy from saturated fat than NDNS intake.Conclusion: We have identified food ingredients which are present in EEN formulas that are effective in Crohn's disease and challenge perceptions that these ingredients might be harmful.

23 August 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
LSLewis Steell
Lewis Steell
SGStuart R Gray
Stuart R Gray
RRRichard K Russell
Richard K Russell
JMJonathan MacDonald
Jonathan MacDonald
JSJohn Paul Seenan
John Paul Seenan
DGDaniel Gaya
Daniel Gaya
Musculoskeletal deficits are among the most commonly reported extra-intestinal manifestations and complications of inflammatory bowel disease (IBD), especially in those with Crohn’s disease. The adverse effects of IBD on bone and muscle are multifactorial, including the direct effects of underlying inflammatory disease processes, nutritional deficits, and therapeutic effects. These factors also indirectly impact bone and muscle by interfering with regulatory pathways. Resultantly, individuals with IBD are at increased risk of osteoporosis and sarcopenia and associated musculoskeletal morbidity. In paediatric IBD, these factors may contribute to suboptimal bone and muscle accrual. This review evaluates the main pathogenic factors associated with musculoskeletal deficits in children and adults with IBD and summarises the current literature and understanding of the musculoskeletal phenotype in these patients.

19 November 2021 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
NSNicholas Simpson
Nicholas Simpson
JSJohn Paul Seenan
John Paul Seenan
RPRajan Patel
Rajan Patel
DKDavid Kipgen
David Kipgen
We present a patient with an acute kidney injury thought secondary to acute interstitial nephritis as a result of vedolizumab maintenance therapy for Crohn’s disease. This appears to be a rare but serious side effect in patients receiving this treatment which clinicians should consider in the event of renal dysfunction.

18 February 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
HAHanoof Abdulrahman Alessa
Hanoof Abdulrahman Alessa
MQMolly Elizabeth Quinn
Molly Elizabeth Quinn
LALinah Alhomidan
Linah Alhomidan
CRCameron Ross
Cameron Ross
SKStefanos Kainadas
Stefanos Kainadas
KGKonstantinos Gerasimidis
Konstantinos Gerasimidis
Background/Objectives: Animal studies have shown that food additives may adversely affect the gut microbiome. However, the effect of food additives on the microbiome in adults with Crohn’s disease (CD) remains less explored. This study investigated the impact of food additives on gut microbiome and fibre fermentation capacity in adults with CD and healthy controls (HCs) using in vitro faecal fermentations. Methods: Faeces from 6 HCs and 6 patients with CD in clinical remission (Harvey Bradshaw Index < 5) were used for in vitro fermentation of a fibre mix with one of 12 food additives (calcium propionate, carboxymethylcellulose, carrageenan kappa, cinnamaldehyde, maltodextrin, polysorbate-80, potassium sorbate, sodium benzoate, sodium sulphite, titanium dioxide, turmeric, and xanthan gum). Short-chain fatty acids (SCFAs) were measured using gas chromatography, the microbiome was profiled with 16S rRNA amplicon sequencing and total bacterial load was measured with qPCR. Results: Maltodextrin increased acetate production in both groups. In HCs, turmeric increased acetate and butyrate production, sodium sulphite reduced acetate production, and maltodextrin reduced butyrate production. Microbiome Shannon α-diversity increased with titanium dioxide (both groups), and with carrageenan kappa only in patients with CD. In both groups, the addition of maltodextrin and polysorbate-80 induced significant shifts in microbiome structure (β-diversity). Significant shifts were seen with maltodextrin (HC: R2 = 6.8%, p = 0.001; CD: R2 = 5.1%, p = 0.004) and sodium sulphite (HC: R2 = 6.9%, p = 0.001). Maltodextrin significantly decreased the estimated absolute abundance of Escherichia–Shigella in patients CD; sodium benzoate, potassium sorbate, and calcium propionate did so in HCs. Faecalibacterium decreased in the presence of polysorbate-80 in the HC and CD groups, as well as in the presence of maltodextrin in the CD group. Total bacterial load decreased with polysorbate-80, potassium sorbate, maltodextrin and calcium propionate in both groups. Xanthan gum decreased total bacterial load in HCs. Conclusion: Certain food additives significantly affected fibre fermentation capacity and microbiome structure, with only modest differences observed according to participants’ health status.

15 January 2020 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PDF file
Vaios SvolosVaios Svolos
Vaios Svolos
KGKonstantinos Gerasimidis
Konstantinos Gerasimidis
VRV Rizou
V Rizou
ECEvangeline Christina
Evangeline Christina
PKP Kapranos
P Kapranos
KGKonstantinos Gerasimidis
Konstantinos Gerasimidis
Treatment with exclusive enteral nutrition (EEN) offers a nutritional therapy paradigm in Crohn’s disease, with the extensive modulation of gut microbiome being its proposed mechanism of action (1). Recent studies propose variable clinical efficacy for 85% EN (Cheat EN/CEN), 50% EN (Partial EN/PEN) and 20% EN (maintenance EN/MEN), and a dose-dependent effect of EN use in CD (2–5). Therefore, this study aims to investigate the dose-dependent effect of 100%, 85%, 50%, and 20% EN on faecal microbial metabolites; and to investigate if this effect can be used as a compliance marker for EEN. Healthy adults followed EEN, CEN, PEN or MEN diet for 7 days. Fresh faecal samples were collected before and after each dietary intervention Dietary assessment was performed throughout the intervention using estimated weight food diaries. Faecal pH, water content, Bristol Stool Chart Score, short-chain fatty acids and hydrogen sulphide were measured. A total of 122 faecal samples were collected from 61 subjects. The Mean(SEM) EN intake for the four groups was EEN: 100(0), CEN: 85.6(0.5), PEN: 50.1(0.4), MEN: 19.9(0.2) % of total energy intake. The baseline levels of all faecal sample measures were no different between the four groups. Faecal water content, propionic acid and Bristol Stool Chart Score significantly decreased only during EEN (all p≤0.03). Faecal pH significantly increased during EEN, CEN and PEN (all p < 0.001), but not during MEN (p = 0.728). Faecal pH post-intervention was highest for EEN, followed by CEN and PEN [Mean(SEM), EEN: 8.2(0.1); CEN: 7.8(0.2); PEN: 7.3(0.1), all pairwise p ≤ 0.002]. The faecal concentration of hydrogen sulphide, acetic and butyric acid significantly decreased following both EEN and CEN groups (all p ≤ 0.009). The concentration of acetic acid post-EEN was significantly lower than the concentration post CEN [Mean(SEM), EEN: 173(10); CEN: 261(24) μmol/g, p = 0.001]. Hydrogen sulphide and butyric acid concentrations post EEN and post CEN were unchanged (p = 0.337, p = 0.141). EEN extensively modulates faecal microbial metabolites and CEN induces similar effects. PEN induces variable effects and further analysis should investigate if variation in responses reflects differences in the non-EN food intake of the participants (50%). MEN had no effect on faecal microbial metabolites. Further analysis including high-throughput deep sequencing techniques will provide additional information about the dose-dependent effect of EN regimen on gut microbiome composition. References 1. Quince et al., Am J Gastroenterol, 110:1718–1729. 2. Logan et al., Aliment Pharmacol Ther, 2019;50:664–674. 3. Gupta et al., IBD, 2013;19:1374–1378. 4. Duncan et al., BMC Gastroenterol, 2014;14:50. 5. Lee et al., IBD, 2015;21:1786–1793.

24 October 2023 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
AGAilsa Gemmell
Ailsa Gemmell
AFAndrew Fraser
Andrew Fraser
KOKarin Oien
Karin Oien
JSJohn Paul Seenan
John Paul Seenan
We present a patient with a drug-induced liver injury with autoimmune features as a result of infliximab therapy for ulcerative colitis. This is a rare but serious side effect in patients receiving this treatment which clinicians should consider in the event of liver function test derangement.